Global Hydrogel-Based Drug Delivery System Market, by Source (Natural, Synthetic, and Hybrid), by Route of Delivery (Oral Cavity, Subcutaneous, Topical, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 4,785.4 Mn in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key players operating in the market are engaged in business development strategies such as merger, acquisition, and collaboration for the development of new drug delivery systems, which in turn, is expected to drive the market growth. For instance, in December 2018, Neurelis, Inc., a neuroscience company, acquired Aegis Therapeutics, a San Diego-based drug delivery technology company. The company’s proprietary portfolio consists of Hydrogel, Intravail, and ProTek, these are 3 non-invasive drug delivery which can be used for a wide range of peptides, therapeutic proteins, and non-peptide macromolecules.
Global Hydrogel-Based Drug Delivery System Market– Impact of Coronavirus (COVID-19) Pandemic
In the midst of COVID-19 pandemic, tremendous efforts are made for the development of efficient ways for prevention and treatment of COVID-19 caused by SARS-CoV-2. According to a research study published pubmed in April 2021, efficient delivery of drugs to the lung is a significant challenge, hence extensive research is taking place in the area of development of new drug delivery.
Moreover, according to a research study conducted by researchers from Stanford University, proves that slow delivery of antigens with the application of hydrogel can result in a more potent immune reaction. According to the same source, the mice vaccinated with the hydrogel system showed higher immunoglobulin G (IgG) titers, subsequently, stronger immune response across the board than the control vaccinations. Hence, the high research and development for the application of hydrogel-based drug delivery systems in delivering COVID-19 therapeutics is expected to drive the market growth over the forecast period.
Browse 44 Market Data Tables and 49 Figures spread through 206 Pages and in-depth TOC on “Global Hydrogel-Based Drug Delivery System Market”- Forecast to 2028, Global Hydrogel-Based Drug Delivery System Market, by Source (Natural, Synthetic, and Hybrid), by Route of Delivery (Oral Cavity, Subcutaneous, Topical, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Hydrogel-Based Drug Delivery System Market, click the link below:
The growing application of hydrogel for the delivery of tumor treatment drugs is further driving the market growth. The delivery of candidate compounds for tumor treatment may have many problems associated such as low bioavailability, greater toxicity, strong hydrophobicity, and instability. According to a study published Informa UK Limited in March 2020, researchers from China developed In-situ hydrogels for improving bioavailability and limiting the side effects of anti-tumor drugs.
Key Takeaways of the Global Hydrogel-Based Drug Delivery System Market:
- Among regions, Asia-Pacific is expected to have the highest growth rate in the global hydrogel-based drug delivery system market over the forecast period, owing to increasing adoption of hydrogel-based systems for efficient drug delivery processes. For instance, in September 2021, researchers from the National Institute of Immunology (NII) and the Regional Centre for Biotechnology (RCB), India, developed a hydrogel-based delivery system that entrapped first-line anti-tuberculosis (TB) drugs namely Rifampicin, Pyrazinamide, Isoniazid, and Ethambutol. This delivery system helped in the prolonged drug delivery for up to 15 days in mice.
- Major players operating in the global hydrogel-based drug delivery system market include Johnson & Johnson, Bausch & Lomb, Ocular Therapeutix, Inc, Tolmar Pharmaceuticals, Inc., Ashland, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Micropore Technologies, Neurelis, Inc., and ProLynx Inc.
